Indian J Med Microbiol Close
 

Figure 3: Psoriasis Area and Severity Index 100 at week 12 across three Phase III studiesa with secukinumab 300 mg in patients with moderate-to-severe psoriasis. *P < 0.001, **P = 0.0003, aComparator in Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis was placebo, in Full Year Investigative Examination of Secukinumab versus Etanercept using Two Dosing Regimens to Determine Efficacy in Psoriasis was etanercept and in Cancer Lifestyle and Evaluation of Risk was ustekinumab

Figure 3: Psoriasis Area and Severity Index 100 at week 12 across three Phase III studies<sup>a</sup> with secukinumab 300 mg in patients with moderate-to-severe psoriasis. *<i>P</i> < 0.001, **<i>P</i> = 0.0003, <sup>a</sup>Comparator in Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis was placebo, in Full Year Investigative Examination of Secukinumab versus Etanercept using Two Dosing Regimens to Determine Efficacy in Psoriasis was etanercept and in Cancer Lifestyle and Evaluation of Risk was ustekinumab